Browse a selection of key resources and publications about our pipeline.

Preliminary Anti-Leukemia Activity From a Phase 1 Study of CLN-049, a Novel Anti-FLT3 x Anti-CD3 Bispecific T-cell Engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (2025 ASH)

CLN-049: A New and Differentiated Approach to Acute Myeloid Leukemia Treatment

CLN-978, a CD19xCD3 T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases (2025 ACR)

Activity of Zipalertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR exon 20 insertion (ex20ins)/Other Uncommon Mutations (2025 ESMO)

Balancing the Immune System With T Cell Engagers

CD19: A Key Target in Treating Autoimmune Diseases

BCMA: A Promising Target in Autoimmune Diseases

2025 WCLC REZILIENT2

2025 WCLC REZILIENT1

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab (2025 JCO)